Featured Research

from universities, journals, and other organizations

MicroRNA variations associated with earlier prostate cancer diagnosis in African-American men

Date:
April 4, 2011
Source:
Fox Chase Cancer Center
Summary:
Prostate cancer is the second leading cause of cancer-related death among American men. Yet screening programs have not reduced the number of deaths. Focusing screening on the men who are at greatest risk for aggressive disease or diagnosis at a young age, could improve mortality rates. Now, researchers have found that two novel genetic markers are associated with earlier time to prostate cancer diagnosis among African American men.

Prostate cancer is the second leading cause of cancer-related death among American men. Yet population-wide screening programs have not reduced the number of deaths from the disease. By focusing screening programs on the men who are at greatest risk for aggressive disease or diagnosis at a young age, researchers think they could improve mortality rates and personalize the screening approach. For that reason, scientists have been looking for genetic markers to help them identify exactly which men are at high risk and require regular screening. Now, Fox Chase Cancer Center researchers have found that two novel genetic markers are associated with earlier time to prostate cancer diagnosis among African American men--and the markers are in a part of the genome that has only recently come under scientific study.

Veda Giri, MD, medical oncologist and director of Prostate Cancer Risk Assessment at Fox Chase, will present the findings at the AACR 102nd Annual Meeting 2011 on Monday, April 4.

Small RNAs, called microRNAs (miRNAs), help regulate gene activity. And expression of these miRNAs can influence an individual's risk of cancer. Knowing this, Giri and her colleagues have been researching genetic variations in miRNA binding sites. In two genes, IL-16 and IL-18, they have now found variations associated with a two-fold or greater increased risk of early prostate cancer diagnosis in African American men who are undergoing screening.

"We have found some preliminary data supporting the idea that genetic variation in miRNA target sites can influence prostate cancer risk," says Giri. "If we confirm these data, then we might be able to use these sites, along with other known genetic variants, to help individualize prostate screening in the future."

Giri notes that although miRNAs were only discovered recently, their role in cancer susceptibility is being rapidly uncovered, probably because they control expression of genes involved in tumor formation, progression, and metastasis. "miRNAs regulate gene expression. If miRNA binding sites are altered then there is a possibility that gene expression would change and could potentially contribute to the cancer process" Giri says.

Giri's team analyzed single nucleotide polymorphisms (SNPs) in miRNA binding sites in four genes of potential importance to prostate cancer risk -- ALOX15, IL-16, 1L-18, and RAF1 -- in approximately 750 men enrolled in the Prostate Cancer Risk Assessment Program at Fox Chase. None of the SNPs were associated with prostate cancer risk in Caucasian men. However, African American men who carried a genetic variant in the miRNA binding site in the IL-16 gene had a 2.27-fold increased risk of early diagnosis, compared with African American men who did not carry the variant. The association was statistically significant (p=0.013).

Additionally, African American men who carried a variant in the miRNA binding site in the IL-18 gene had a 4.44-fold increased risk of early diagnosis, compared with men who did not. Giri cautions, though, that this association had a relatively weak statistical association (p=0.042) and needs to be followed up in a larger study.

"Our goal is to develop individualized prostate cancer screening approaches, particularly for high-risk men," Giri says. "Therefore, our research is focused on identifying which men may develop lethal or clinically meaningful prostate cancer in order to screen these men for benefit, while sparing other men unnecessary tests and procedures. Down the road, these new markers may help us do that."

L. Hughes and K. Ruth from Fox Chase are co-authors on the study.


Story Source:

The above story is based on materials provided by Fox Chase Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

Fox Chase Cancer Center. "MicroRNA variations associated with earlier prostate cancer diagnosis in African-American men." ScienceDaily. ScienceDaily, 4 April 2011. <www.sciencedaily.com/releases/2011/04/110404084325.htm>.
Fox Chase Cancer Center. (2011, April 4). MicroRNA variations associated with earlier prostate cancer diagnosis in African-American men. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/04/110404084325.htm
Fox Chase Cancer Center. "MicroRNA variations associated with earlier prostate cancer diagnosis in African-American men." ScienceDaily. www.sciencedaily.com/releases/2011/04/110404084325.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins